Lek Pharmaceuticals D.d.

Lek, Tovarna Farmacevtskih in Kemicnih Izdelkov, D.d.

Univerza V Ljubljani, Fakulteta Za Naravoslovje in Technologijo, Oddelek

Uros Urleb

Anton Copar

Barbara Podobnik

Danijel Kikelj

Breda Bole-Vunduk

Rudolf Rucman

Igor Krisch

Natasa H Milac

Mojca Stegnar

Anamarija Zega

Ales Krbavcic

Marija Sollner

Srdjan Novakovic

Anton Stalc

Lucka Povsic

Gregor Sersa

Gasper Marc

Elizabeta Suhadolc

Alenka Rutar

Slavko Pecar

Alesa Puncuh

Gregor Mlinsek

Marko Zivin

Natasa Milivojevic

Andreja C Belcic

Alenka Kosak

Brina Ornik

Andrej Prezelj

Bakija Alenka Trampus

Tomaz Solmajer

Vesna Leskovsek

Marija Bogataj

Manica Cerne

Doris Tibaut

Ales Mrhar

Greta Cof

Fumio Yoneda

Janez Kerk

Tatjana Mateovic

The present invention belongs to the field of pharmaceutical industry and relates to a new method for the treatment of psychostimulant addiction, in particular cocaine addiction, or pharmaceutically acceptable acid addition salts thereof, with a therapeutically effective amount of 9,10-didehydro-N-methyl-N-(2-propy-nyl)-6-methyl-8&#x3b2;-aminomethylergo-line in the form of free base or in the form of pharmaceutically acceptable addition salt, in particular the bimaleate salt, as well as pharmaceutical compositions containing said compound. In literature, the compound is also known under code LEK-8829. More particularly, present invention relates to a novel method of treatment for reduction of abstinence symptoms after cocaine withdrawal and for suppression the symptoms of craving for cocaine withdrawal and for suppression the symptoms of craving for cocaine reinforcement, and to the use of said active substance for the preparation of the pharmaceutical composition for the treatment of cocaine addiction. In addition to the treatment of cocaine addiction, the present invention also relates to the method for treatment of the addiction with amphetamine, methamphetamine, dextroamphetamine, 3,4-methylenedioxymethamphetamine and pemoline or acid addition salts thereof.

Treatment of psychostimulant addiction

A novel crystalline form of the substrate known under the chemical name 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfiny]-1H-benzimidazole, and having the generic name omeprazole, hereinafter referred to as omeprozole form C, is disclosed. Further, a process for the preparation of omeprazole form C, a pharmaceutical formulation containing omeprazole form C in admixture with pharmaceutically acceptable excipients and the use of omeprazole form C for treatment of gastrointestinal disorders are disclosed.

Crystalline form of omeprazole

The compounds of the formula (formula 1) and pharmaceutically acceptable salts thereof and a process for preparing the same and pharmaceutical compositions containing the same are described wherein the substituents have the meaning as specified in the description. The compounds are used as thrombon inhibitors.

Amidinophenylalanine derivatives as thrombin inhibitors

Heterocyclic acyldipeptides, processes for the preparation thereof and

Growing community of inventors

Ljubljana, Slovenia

Uros Urleb